Biotechnology & Medical Research

Page 2

Sosei Group Corp acquires Heptares Therapeutics for up to $400 million

Sunday, 22 Feb 2015 07:00pm EST

Sosei Group Corp:Announces that it has acquired Heptares Therapeutics Limited (Heptares), a clinical-stage private UK-based biotechnology company focused on creating novel medicines targeting G protein-coupled receptors.Says that the acquisition is for up to $400 million.

M Pharmaceutical Inc closes eMosquito Acquisition

Thursday, 19 Feb 2015 01:23pm EST

M Pharmaceutical Inc:Finalizes acquisition of the intellectual property associated with the eMosquito by the purchase of M Diagnostics Inc., a private company.Company paid $ 150,000 on closing.Agreed to pay a three pct royalty on the commercial sale of any related products, and issued 8,066,670 common shares, which are subject to a 3 year escrow, with 10 pct being immediately releasable, and the balance in 6 equal installments over the next 3 years.Also entered into an agreement to sell its remaining oil and gas and mining assets to an arms-length private company for a deemed price of $250,000, payable by the issue of 10,000,000 private company shares at a deemed price of $0.025.Company is actively looking at other strategic medical devices to add to its portfolio so as to diversify its product mix and reduce market sector risk.

Genus to acquire 51 pct of In Vitro Brasil S.A

Monday, 16 Feb 2015 02:00am EST

Genus PLC:Signs an agreement for the acquisition of 51 pct of the share capital of In Vitro Brasil S.A. (IVB) through ABS, its bovine genetics business.Says IVB is based in Brazil and also operates in a number of countries including the US, Colombia and Uruguay.Genus will acquire a 51 pct interest in IVB for a total investment consideration of BRL 20 million (4.6 mln Pounds) in cash, including an upfront capital commitment.Genus expects to acquire the remaining 49 of IVB's share capital in the first half of 2018 by exercising a call option.The selling shareholders also have a matching put option. Consideration for the remaining 49 pct is conditional on certain performance conditions and is capped at BRL 49 million (11.mln Pounds).The completion of the transaction is subject to a number of closing conditions, which are expected to be fulfilled in the first quarter of 2015.In 2014, IVB had global revenues in excess of 4 million Pounds.

Gimv announces Intrexon acquired portfolio company Actogenix

Friday, 13 Feb 2015 08:41am EST

Gimv NV:Gimv portfolio company Actogenix acquired by Intrexon corporation.Consummation of the transaction is anticipated in the first quarter.Actogenix' shareholders will receive about $30 million in cash and $30 million in Intrexon common stock.Sale has a marginal positive impact on Gimv's last published equity value.

Eurofins Scientific announces acquisition of Biodiagnostics Inc

Wednesday, 11 Feb 2015 02:00am EST

Eurofins Scientific SE:Announces acquisition of Biodiagnostics Inc.Biodiagnostics Inc is seed and plant-tissue testing laboratory serving the agricultural industry in the United States.

Qiagen Marseille accepts 1.2 mln euro offer from HalioDx for assets; Qiagen NV launches tender offer for Qiagen Marseille shares

Monday, 9 Feb 2015 05:25am EST

Qiagen Marseille SA:Qiagen NV decided to launch a voluntary tender offer in respect of shares of Qiagen Marseille, at a price of 14.90 euros per share.This offer price valuates Qiagen Marseille at about 81.1 million euros.

JSR offers takeover bid for shares of Medical&Biological Laboratories

Monday, 9 Feb 2015 02:30am EST

JSR CORP:JSR offered a takeover bid for 4,674,000 shares (or no more than 4,674,000 shares) of Medical&Biological Laboratories.Offered purchase price at 600 yen per share.Takeover bid total amount at 2,804,400,000 yen.Offering period from Feb. 10 to March 11.Settlement starts on March 18.To hold 51 pct voting rights in Medical&Biological Laboratories, up from 33.10 pct.

Miraca Holdings completes acquisition of stake in Baylor Miraca Genetics Laboratories

Tuesday, 3 Feb 2015 01:15am EST

Miraca Holdings Inc:Acquired 60 pct stake in Baylor Miraca Genetics Laboratories, LLC (BMGL) from Baylor College of Medicine (BCM), through Miraca USA, Inc.BMGL is a company engaged in provision of genetic testing service, which will be established by BCM.Plan disclosed on Oct. 31, 2014.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.